Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.00 |
---|---|
High | 7.27 |
Low | 6.88 |
Bid | 7.10 |
Offer | 7.11 |
Previous close | 6.95 |
Average volume | 1.41m |
---|---|
Shares outstanding | 137.72m |
Free float | 121.40m |
P/E (TTM) | -- |
Market cap | 957.15m USD |
EPS (TTM) | -3.92 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 20:49 GMT.
More ▼
- Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
- Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency
- Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting
- Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
- Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024
- Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD’s The Liver Meeting® 2024
- Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
- Vir Biotechnology Appoints Jason O’Byrne as Chief Financial Officer
- Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers
More ▼